All News Tetra Bio-Pharma Inc.

Equities

Delayed OTC Markets Other stock markets 14:30:00 16/05/2024 BST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-99.83%

Acute Pain Pipeline, Clinical and Non-Clinical Stages Products, and FDA Approvals 2023 (Updated)	27/09/23	AQ
Tetra Bio-Pharma Announces Listing to OTCPink Market	10/02/23	PR
REDUVO™ Marketing Approval on the Right Path	22/12/22	PR
Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir	06/12/22	PR
Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003	29/11/22	PR
Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean	27/10/22	PR
Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients	06/09/22	PR
Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections	10/08/22	PR
Tetra Bio-Pharma Appoints Chief Financial Officer	30/05/22	PR
Tetra Bio-Pharma Receives $4.5M from the Ministère de l'Économie et de l'Innovation/Investissement Québec	16/02/22	PR
Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna	14/02/22	PR
QIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation Aerosols	29/11/21	PR
Tetra Bio-Pharma Inc. Announces Termination of "At-The-Market" Offering	05/11/21	PR
Tetra Bio Pharma : Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency	21/10/21	PR
Tetra Bio Pharma : REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.	05/10/21	PR

No results for this search